2. 周文盛,张伟,韩宝惠,EGFR基因20外显子插入突变在非小细胞肺癌的研究及其进展. 中国肺癌杂志 2 0 2 0年 2月第 2 3卷第 2期 3.Janssen announces U.S. FDA breakthrough therapy designation granted for JNJ-6372 for the treatment of non-small cell lung cancer [news release]: Raritan, NJ. Publi...
RARITAN, NJ, May 13, 2020-- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen...
Janssen Research & Development, Raritan, NJ, USA Nibedita Bandyopadhyay UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA Lawrence Fong Contributions C.G.D., R.K.P., S.K.S., D.G.M., E.S.A., T.M.B., and L.F. were involved in data acquisition and ana...
Kevin ShalaydaJanssen Research & Development LLC, Raritan NJ USALucille RussellJanssen Research & Development LLC, Raritan NJ USAPanna SangaJanssen Research & Development LLC, Raritan NJ USAYinka WilliamsJanssen Research & Development LLC, Raritan NJ USABhavna Solanki...
(Raritan, NJ). JNJ‑26366821 was supplied to AFRRI in a powder form and it was formulated in sterile normal saline (0.9% NaCl) before use and protected from light22. Either drug or its vehicle was injected subcutaneously (SC) at the nape of the neck, pre-TBI at the time indicated ...
3.Janssen announces U.S. FDA breakthrough therapy designation granted for JNJ-6372 for the treatment of non-small cell lung cancer [news release]: Raritan, NJ. Published March 10, 2020. https:///2Q0EhsA. Accessed March 10, 2020. ...